|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008059,
umls-concept:C0013089,
umls-concept:C0020823,
umls-concept:C0042679,
umls-concept:C0079459,
umls-concept:C0183683,
umls-concept:C0205653,
umls-concept:C0282460,
umls-concept:C0344211,
umls-concept:C0600558,
umls-concept:C1171411,
umls-concept:C1261473,
umls-concept:C1317973,
umls-concept:C1518932,
umls-concept:C1521721,
umls-concept:C2603343
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2005-6-17
|
|
pubmed:abstractText |
To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4031-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15767644-Adolescent,
pubmed-meshheading:15767644-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15767644-Child,
pubmed-meshheading:15767644-Combined Modality Therapy,
pubmed-meshheading:15767644-Doxorubicin,
pubmed-meshheading:15767644-Female,
pubmed-meshheading:15767644-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:15767644-Humans,
pubmed-meshheading:15767644-Ifosfamide,
pubmed-meshheading:15767644-Male,
pubmed-meshheading:15767644-Mesna,
pubmed-meshheading:15767644-Neoadjuvant Therapy,
pubmed-meshheading:15767644-Protective Agents,
pubmed-meshheading:15767644-Sarcoma,
pubmed-meshheading:15767644-Soft Tissue Neoplasms,
pubmed-meshheading:15767644-Survival Analysis,
pubmed-meshheading:15767644-Treatment Outcome,
pubmed-meshheading:15767644-Vincristine
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
|
|
pubmed:affiliation |
The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G1X8, Canada. alberto.pappo@sickkids.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
